cenicriviroc

an inhibitor of HIV-1

Also Known As:

(-)-8-(4-(2-butoxyethoxy)phenyl)-1-isobutyl-n-(4-(((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide; 8-(4-(2-butoxyethoxy)phenyl)-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-(4-((S)-((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1-benzazocine-5-carboxamide; TAK 652; TAK-652; TBR 652; TBR-652; TBR652

Networked: 46 relevant articles (9 outcomes, 20 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lefebvre, Eric: 8 articles (01/2021 - 02/2014)
2.	Tacke, Frank: 7 articles (01/2022 - 01/2018)
3.	Fischer, Laurent: 6 articles (01/2021 - 03/2016)
4.	Ratziu, Vlad: 5 articles (01/2020 - 03/2016)
5.	Sanyal, Arun: 5 articles (01/2020 - 03/2016)
6.	Seyedkazemi, Star: 5 articles (01/2020 - 01/2018)
7.	Goodman, Zachary: 4 articles (01/2020 - 03/2016)
8.	Friedman, Scott L: 3 articles (01/2022 - 01/2016)
9.	Kowdley, Kris V: 3 articles (09/2021 - 01/2018)
10.	Abdelmalek, Manal F: 3 articles (01/2020 - 01/2018)

Related Diseases

1.	Non-alcoholic Fatty Liver Disease 01/01/2022 - "The FPS was used to assess response to 13 candidate antifibrotics in organotypic ex vivo cultures of clinical fibrotic liver tissues (n = 78) and cenicriviroc in patients with nonalcoholic steatohepatitis enrolled in a clinical trial (n = 19, NCT02217475). " 12/28/2018 - "Role of cenicriviroc in the management of nonalcoholic fatty liver disease." 04/13/2023 - "Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study." 01/01/2020 - "Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study." 01/01/2020 - "Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design."
2.	Liver Cirrhosis (Hepatic Cirrhosis) 01/01/2023 - "Pharmacological CCR2 inhibition with cenicriviroc (CVC) reduced ECM accumulation and liver fibrosis in prevention and treatment administration. " 04/13/2023 - "Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study." 01/01/2020 - "Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design." 03/01/2016 - "Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design." 03/01/2018 - "Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis."
3.	Fibrosis (Cirrhosis) 01/01/2022 - "Induction of the PPARα pathway was absent in patients without fibrosis improvement, suggesting a benefit of combining PPARα agonism to improve the antifibrotic efficacy of cenicriviroc. " 09/01/2021 - "≥1-point improvement in fibrosis with no worsening of NASH was shown in patients treated with cenicriviroc. " 12/01/2021 - "Our further findings indicate that on the basis of the administration of CCR2/CCR5 dual inhibitor Cenicriviroc, further inhibiting MoMFs SYK may give patients with fibrosis additional benefits." 01/01/2016 - "Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis." 01/01/2020 - "Herein we review results from the phase 2b CENTAUR trial and study designs for the phase 2b TANDEM and phase 3 AURORA trials and discuss the potential role of cenicriviroc in future pharmacotherapy for NASH fibrosis."
4.	Graft vs Host Disease (Graft-Versus-Host Disease) 01/01/2020 - "Erratum: Cenicriviroc ameliorates the severity of graft-versus host disease through inhibition of CCR5 in a rat model of liver transplantation." 01/01/2019 - "Cenicriviroc ameliorates the severity of graft-versus-host disease through inhibition of CCR5 in a rat model of liver transplantation."
5.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2023 - "The study was designed to assay the efficacy of cenicriviroc (CVC) on the progression of mouse colorectal cancer by downregulation of CCR2_CCL2. " 01/01/2023 - "Promising Modulatory Effects of Cenicriviroc on the Progression of Mouse Colorectal Cancer through Inhibition of CCR2_CCL2 Signaling Pathway."

Related Drugs and Biologics

1.	Chemokine Receptors
2.	tropifexor
3.	obeticholic acid
4.	selonsertib
5.	2- (2,6- dimethyl- 4- (3- (4- (methylthio)phenyl)- 3- oxo- 1- propenyl)phenoxyl)- 2- methylpropanoic acid
6.	3- (2- (2- tert- butylphenylaminooxalyl)aminopropionylamino)- 4- oxo- 5- (2,3,5,6- tetrafluorophenoxy)pentanoic acid
7.	Peroxisome Proliferator-Activated Receptors (PPAR)
8.	lanifibranor
9.	Opioid Analgesics (Opioids)
10.	4- (3- amino- 4- (2,4,5- trifluorophenyl)butanoyl)- 3- (tert- butoxymethyl)piperazin- 2- one

Related Therapies and Procedures

1.	Liver Transplantation
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)
4.	Spinal Injections
5.	Analgesia